[6]Schmidt G, Gerlinger C, Juhasz-Böss I, et al. Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer. J Cancer Res Clin Oncol. 2016 Jun;142(6):1369-76. [7]Xu H, Han Y, W...
[7] Lambein K, Van Bockstal M, Vandemaele L, et al. Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance. Am J Clin Pathol. 2013 Oct;140(4)...
Particularly, the impact of Her2-neu score 0 versus Her2-neu score 1 and 2 on survival was investigated. Materials and methods: We retrospectively studied a cohort of 1013 patients with TNBC, diagnosed at seven hospitals between May 2002 and February 2015. We studied the impact of Her2-neu ...
Her-2/neu基因的蛋白 CerbB-2 ● 癌细胞表面存在着CerbB-2蛋白, 受刺激后促进癌细胞的增殖 刺激 増殖 がん細胞 ● 20～30%的癌细胞 Heceptin:一种针对Her-2/neu 受体的高纯度重组DNA衍生物的人源化 单克隆抗体,是乳腺癌治疗领域的第一 个分子靶向性药物,具有高效、低毒、 选择性强的特点 ●与CerbB-...
H-score=1×"低"比例+2×"中"比例+3×"高"比例。仅1/9患者(MGH009)H-score差异>1(复发时表达升高)。(C)代表性图像显示治疗前与复发匹配CTC的TROP2表达及细胞形态学特征(包括CTC簇形成)无变化。(D)7例患者治疗前与进展时CTC的HER2表达分布条形图(含20mL标准化CTC数量及时间点)。(E)散点图展示7例患者...
點數呢D悶野留返比醫生,你知佢點匯報得喇。一般佢會比一個叫c-erbB2 score你,有D報告寫HER2/neu,其實都係講同一樣野。佢有4個可能性:0,1+,2+,3+。呢度好多病友搞錯以為「+就等如陽性、等如係HER2型」,呢個係錯嘅。你可以睇成+代表有天線,數字先反影有幾多天線。最終就會係咁: ...
J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987). Article CAS PubMed Google Scholar Chang, J. C. HER2 inhibition: from discovery to clinical practice. Clin. Cancer Res. 13, 1–3 (2007). ...
The HER2 gene (also known as HER2/neu, c-erbB-2) is located at 17q12 and is a member of the epidermal growth factor receptor (HER) family, which plays an important regulatory role in cellular physiological processes. The Luminal B BRCA subtype is characterized by its highly proliferative, ...
曲妥珠单抗/HER2(PDB代码1N8Z)复合物和帕妥珠单抗/HER2复合物(PDB代码1S78)的结构用于建模。可采用分子动力学(MD)评价WT复合物在水环境中的内在动态性质。平均场和死端排除法连同柔性骨架可用于优化和制备待筛选突变体的模型结构。包装后将为许多特征评分,包括接触密度、碰撞得分(clashscore)、疏水性和静电。一般...
Between HER2-low primary BC with different HER2 IHC score, the discordance rate of metastases had no significant difference. In particular, discordant rate of HER2 status was 29.1% (n = 16/55) and 25.6% (n = 11/43) when primary BC was HER2-1+ and HER2-2+, respectively (p...